首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷 CT/MRI/X光

市場調查報告書

商品編碼

1345417

全球光學相干斷層掃描市場 - 2023-2030

Global Optical Coherence Tomography Market - 2023-2030

出版日期: 2023年09月06日 | 出版商:

DataM Intelligence | 英文 186 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

全球光學相干斷層掃描市場於2022年達到15億美元，預計到2030年將達到28億美元，2023-2030年預測期間年複合成長率為8.7%。

光學相干斷層掃描利用光對組織排列進行微米級、原位、即時的橫截面成像。這是一種非侵入性成像程序，用於進行光學活體組織切片。它用於無法使用傳統成像方法的場所。 OCT建立在光纖基礎上，可以與導管、腹腔鏡、內視鏡和手術探針等工具結合，方便對身體進行成像。

在玻璃體視網膜疾病治療中，OCT 相對於檢眼鏡檢查的一個顯著優勢是能夠限制玻璃體、視網膜和視網膜外膜之間的3D關聯。 OCT的應用範圍包括各種眼部疾病的診斷，如黃斑裂孔、黃斑水腫、黃斑皺褶、青光眼、年齡相關性黃斑部病變、中心性漿液性視網膜病變、玻璃體牽引、糖尿病視網膜病變等。目前，OCT還用於診斷其他疾病的檢測和診斷，例如心血管疾病、非黑色素瘤皮膚癌、前列腺癌和年齡相關性黃斑疾病等。

光學相干斷層掃描主要受到眼科疾病病例不斷增加、市場發展不斷增加（包括合併、收購和產品發布等）的推動。此外，人們日益努力地宣傳眼科疾病，以及心血管疾病、非黑色素瘤皮膚癌、前列腺癌和年齡相關性黃斑疾病等其他慢性疾病病例的增加，也促進了全球眼科疾病市場的成長。預測期。

動力學

眼科疾病病例不斷增加

早期檢測和監測對於青光眼的診斷和治療至關重要，青光眼是一種導致不可逆失明的晚期視神經病變。光學相干斷層掃描 (OCT) 已發展成為一種常用的成像方式，有助於檢測和監測結構性青光眼惡化。因此，糖尿病視網膜病變的高患病率預計將在預測期內推動全球市場的成長。例如，糖尿病視網膜病變涉及由於血液中的高血糖水平而對眼睛視網膜造成的損傷。這是一種複雜的糖尿病，影響著數百萬 1 型和 2 型糖尿病患者。

此外，其他眼科疾病病例的增加預計也將促進預測期內全球市場的成長。例如，根據世界衛生組織 2023 的數據，全球至少有 22 億人存在近視力或遠視力障礙，其中約 10 億人的視力障礙本來可以避免或尚未得到處理。在國際範圍內，視力障礙和失明的主要原因是屈光障礙和白內障。

在這10 億人中，導致遠視力障礙或失明的主要疾病包括影響超過9400 萬人的白內障、影響約8840 萬人的屈光不正、影響超過800 萬人的年齡相關性黃斑部病變、影響約770萬人的青光眼和糖尿病視網膜病變病例超過 390 萬例。導致近視力損傷的主要疾病是老花眼，這是一種與年齡相關的疾病，約有 8.26 億人受到影響。

市場開發數量不斷增加

不斷增加的市場發展，包括合併、合作、產品發布和收購等，正在推動預測期內的全球市場成長。例如，海德堡工程公司於 2021 年 11 月推出了 Spectralis 平台，該平台配備移位技術，可提高 OCTA 和 OCT 的生產率，並允許臨床醫生切換 OCT 掃描速度，以實現更好的個性化評估。 Spectralis 平台提供三種掃描速率：20 kHz、85 kHz 和 125 kHz。

此外，佳能新加坡公司於2021 年7 月推出了Xephilio OCT-S1，這是一種創新的寬視場掃源光學相干拓撲技術，能夠在單次掃描中捕獲高達23×20 毫米的高解析度圖像。此外，2021 年 6 月，Perimeter Medical Imaging AI, Inc. 與 Minnetronix Medical 進行了光學相干斷層掃描 (OCT) 成像系統生產製造方法的技術轉讓。 2021 年 10 月，NIDEK 再次推出了 Retina Scan Duo 2，它整合了眼底相機和 OCT。 Retina Scan Duo 2 具有增強篩查和臨床有效性的特性，還有助於增強臨床工作流程。

光學相干斷層掃描設備成本高

光學相干斷層掃描設備的高成本預計將阻礙全球市場的成長，因為成本高，資本投資低的從業者無力購買新設備，而是使用翻新設備，從而減緩了市場成長。例如，蔡司的 PRIMUS 200 價格約為 19,999.00 美元，同一製造商的 OCT cirrus 5000 價格約為 15,999.00 美元，Topcon OCT 2000 和 DRI OCT Triton 的價格分別約為 7,500.00 美元和 12,900.00 美元。

光學相干斷層掃描設備的成本根據所包含的功能而有所不同，具有高級功能的設備比具有基本功能的設備成本更高，例如Optovue 的iScan OCT 成本約為12,000.00 美元，因為它包含一些高級功能，可以簡化操作，而ivue來自同一製造商的 OCT 價格約為 9,999.00 美元，具有基本功能。

眼科醫生勞動力短缺

眼科醫生勞動力的短缺預計將在預測期內減緩全球市場的成長。例如，根據英國皇家眼科醫師學院的數據，NHS 眼科服務的大部分都面臨著巨大的能力壓力，超過四分之三(76%) 的團隊沒有足夠數量的顧問來滿足現有患者的需求，甚至更多超過一半 (52%) 的人發現在過去 12 個月內招聘顧問也同樣具有挑戰性。

此外，2023年1月，全英格蘭有超過632,000名眼科患者等待檢查，其中24,000名患者等待時間超過一年。與 12 個月前相比，大約 74% 的眼科單位還擔心門診積壓對患者維護的影響，63% 的眼科單位評估可能需要一年多的時間才能緩解門診積壓。此外，勞動力缺乏 NHS 眼保健援助的情況預計將會減少，英國四分之一（26%）的眼科醫生考慮在未來五年內退出勞動力隊伍。

Overview

Global Optical Coherence Tomography Market reached US$ 1.5 billion in 2022 and is expected to reach US$ 2.8 billion by 2030, growing with a CAGR of 8.7% during the forecast period 2023-2030.

Optical coherence tomography utilizes light for the cross-sectional imaging of the tissue arrangement on the micron scale, in situ, and in real time. It is a non-invasive imaging procedure, which is employed to conduct optical biopsies. It is employed in sites where conventional imaging approaches cannot be utilized. OCT is established on fiber optics and can be combined with the tools, like catheters, laparoscopes, endoscopes, and surgical probes, which facilitate imaging of the body.

A significant benefit of OCT over the ophthalmoscopic investigation in vitreoretinal disorder management is the capacity to confine three-dimensional associations between the vitreous, retina, and extraretinal membranes. The applications of OCT enclose the diagnosis of various eye disorders such as the macular hole, macular edema, macular pucker, glaucoma, age-related macular degeneration, central serous retinopathy, vitreous traction, diabetic retinopathy, etc. Presently, OCT is also utilized for the detection and diagnosis of other additional disorders such as cardiovascular diseases, non-melanoma skin cancer, prostate cancer, and age-related macular disease, among other.

The Optical coherence tomography is primarily boosted by the growing cases of opthalmic disorders, increasing market developments including mergers, acquisitions, and product launches among others. Further, the increasing efforts to spread awareness about opthamic disorders and growing cases of other chronic disorders including cardiovascular disorders, non-melanoma skin cancer, prostate cancer, and age-related macular disease, among others are also contributing to the global market growth in the forecast period.

Dynamics

Increasing Cases of Ophthalmic Disorder

Early detection and monitoring are essential to the diagnosis and management of glaucoma, an advanced optic neuropathy that induces irreversible blindness. Optical coherence tomography (OCT) has evolved into a typically employed imaging modality that assists in the detection and monitoring of structural glaucomatous deterioration. Thus, the high prevalence of diabetic retinopathy is expected to boost the global market growth during the forecast period. For instance, the diabetic retinopathy concerns injury to the eye's retina owing to high blood sugar levels in the blood. It is an expected intricacy of diabetes, impacting millions of individuals with both type 1 and type 2 diabetes.

Further, the growing cases of other ophthalmic disorders are also expected to be contributing to the global market growth in the forecast period. For instance, according to the WHO 2023, globally, at least 2.2 billion individuals are with near or distant vision impairment, and out of these around 1 billion vision impairment could have been averted or is yet to be handled. The top reasons for vision impairment and blindness at a multinational level are refractive disorders and cataracts.

Among these 1 billion individuals, the primary disorders inducing distance eyesight impairment or blindness include cataracts affecting over 94 million individuals, refractive error impacting around 88.4 million people, age-related macular degeneration with over 8 million cases, glaucoma affecting about 7.7 million individuals, and the diabetic retinopathy with over 3.9 million cases. The major disorder inducing near eyesight impairment is presbyopia an age-associated disease with around 826 million individuals impacted.

Increasing Number of Market Developments

The increasing number of market developments including, mergers, collaboration, product launches, and takeovers, among others are boosting the global market growth in the forecast period. For instance, in November 2021, Heidelberg Engineering revealed the Spectralis platform, which is provided with shift technology, improves productivity in OCTA and OCT, and also allows clinicians to switch OCT scan pace for a better-personalized assessment. The Spectralis platform delivers three scan rates, 20 kHz, 85 kHz, and 125 kHz.

Moreover, in July 2021, Canon Singapore introduced the Xephilio OCT-S1, an innovative wide-field swept-source optical coherence topography competent for capturing high-resolution images of up to 23×20 mm in a single scan. Also, in June 2021, Perimeter Medical Imaging AI, Inc. conducted the technology transfer of its manufacturing methodology for the production of its optical coherence tomography (OCT) imaging systems with Minnetronix Medical. Again, in October 2021, NIDEK introduced the Retina Scan Duo 2, an integration of a fundus camera and OCT. The Retina Scan Duo 2 is provided with characteristics that enhance screening, and clinical effectiveness, and additionally helps enhance clinical workflow.

High Optical Coherence Tomography Device Cost

The high cost of the optical coherence tomography devices is expected to hamper the global market growth as due to the high cost the practitioners with low capital investments can not afford to buy a new device and instead of which use refurbished ones, slowing the market growth. For instance, the PRIMUS 200 from Zeiss costs around US$ 19,999.00, the OCT cirrus 5000 from the same manufacturer costs about US$ 15,999.00, Topcon OCT 2000 and DRI OCT Triton both from Topocon costs about US$ 7,500.00 and US$ 12,900.00 respectively.

The optical coherence tomography device cost varies based upon the features included the device with advanced features costs more compared to the one with basic features for example iScan OCT from Optovue costs around US$ 12,000.00 as it includes some advanced features which deliver simplified operations while the ivue OCT from the same manufacturer costs about US$ 9,999.00 having basic features.

Opthalmologists Workforce Shortage

The shortage of ophthalmologists workforce is expected to slow the global market growth during the forecast period. For instnace, according to the Royal College of Ophthalmologists, the extensive bulk of NHS ophthalmology services are encountering substantial capability stresses, with more than three-quarters (76%) of teams not including an adequate number of consultants to satisfy existing patient needs and more than a half (52%) discovering it is additionally challenging to recruit consultants over the previous 12 months.

Moreover, in January 2023, there were more than 632,000 patients on ophthalmology waiting checklists in England sole and 24,000 of which were waiting for more than a year. Around 74% of eye units are additionally concerned regarding the effect of outpatient backlogs on patient upkeep than they were 12 months back and 63% assess it might take over a year to alleviate their outpatient backlogs. Further, the workforce's lack of NHS eyecare assistance is expected to decline, with a quarter (26%) of ophthalmologists in the UK thinking to exit the workforce over the next five years.

Segment Analysis

The global optical coherence tomography market is segmented based on product type, volume scan, technology, application, end-user and region.

Cancer Application of OCT Expected to Dominate Market

The oncology application of the OCT is expected to dominate the global market owing to the increasing number of positive outcomes from investigations intended to assess the efficacy of OCT in cancer diagnosis. For instance, in an investigation, investigators corresponded the diagnostic precision of clinical and dermoscopic examination (CDE) with that of CDE integrated with OCT for detecting recurrent or residual BCC post topical therapy of superficial BCC. When utilized in integration with the clinical and dermoscopic study, optical coherence tomography remarkably enhanced the capability to notice recurrent or residual basal cell carcinomas post-topical treatment.

Moreover, in July 2023, a transnational group of investigators improved the procedure of optical coherence tomography (OCT) which carries importance for ophthalmology, dermatology, cardiology, and the early diagnosis of cancer. The work was instructed by the University of Adelaide, Technical University of Denmark (DTU), Aerospace Corp., and the University of St. Andrews.

Also, in August 2022, the Lancet Oncology presented ground-breaking conclusions on Michelson Diagnostics, the UK-based medical device corporation that uses multi-beam Optical Coherence Tomography ('OCT') technology, which can convert patient therapy and maintenance of basal cell carcinomas (BCC). It was inferred that OCT-guided diagnosis, when corresponding to a classic punch biopsy could decrease the number of consultations and invasive approaches by a huge 66%.

Geographical Penetration

Increasing Number of Ophthalmic Disorders Cases in North America

The increasing prevalence of ophthalmic disorders in North America is expected to boost regional market growth in the forecast period. For instance, in the United States independently, almost 12 million individuals aged 40 and overhead encountered eyesight impairment, with almost a million suffering from blindness. The CDC notifies that 17.2% of Americans above 40 years of age have a cataract in at least one eye accounting for around 20.5 million individuals. By 2028, above 30 million individuals are expected to suffer from cataracts. The CDC assesses that 4.1 million Americans are impacted with diabetic retinopathy, and almost 900,000 Americans are threatened with vision-damaging retinopathy.

With the growth in life expectancy, diabetes, and other chronic conditions, the cases of eye disorders are anticipated to increase twofold by the year 2050. Age-related macular degeneration (AMD) is the highly expected reason for irreversible eyesight loss in older adults (70 years and older), with an assessed 9 million Americans suffering from intermediate or progressive AMD. Moreover, in 2021, an assessed 9.6 million individuals in the United States, 26% of those having diabetes encountered eye disease, and almost 2 million suffered the most extreme form, "vision-threatening diabetic retinopathy" (VTDR).

Further, the increasing government initiatives to fight against the growing prevalence of eye disorders in the region also contribute to the regional market growth in the forecast period. For instance, in December 2022, congress declared its long-awaited Fiscal Year (FY) 2023 expenditure ruling, which retains a sum of $6.5 million for vision and eye health agendas at the Centers for Disease Control and Prevention (CDC).

In certain, the omnibus spending ruling would sponsor the Vision Health Initiative (VHI) at $2.5 million in FY2023, a $1 million growth over FY2022. The addition would support measures to revise national preponderance assessments on vision impairment and eye disorder. The CDC's Glaucoma project, which supports community-based agendas that unite high-risk patients to eye care, would persist to be sponsored at $4 million.

COVID-19 Impact Analysis

Presently, ophthalmic practice widely relies on optic coherence tomography (OCT) and optical coherence tomography angiography (OCT-A), which are objective, reliable, and repeatable structural difficulties for both earlier diagnosis and detection of the advancement of various ocular conditions. The missed clinic visits advanced dramatically during the COVID-19 pandemic, particularly among elderly and nonwhite patients. These findings reflect differences in eye care delivery during the pandemic and they indicate possibilities to target barriers to care, even during non-pandemic eras.

However, individuals responded in diverse patterns to COVID-19 conditions. While some individuals produced mild to extreme respiratory issues, others encounter no manifestations at all. Pink eye remained the most typical manifestation of COVID in the eyesight of children and adults. Thus, COVID-19 is estimated to hold intermediate impact over the global market growth in the forecast period.

Russia-Ukraine Impact

The Russia Ukraine conflict is expected to have a very little impact over the global market, since the foremost weeks of the attack, Eyes on Ukraine, a humanitarian effort directed by ophthalmologists from across the nation, has been raising funds and shipping medication and surgical supplies to Ukraine ophthalmologists, with multiple reports from hospitals and war crews close to the front that the cargoes are making a general distinction.

Obtaining reserves into the nation, however, has demanded invention and the forging of a trusted network of people, including European ophthalmologists and Polish and Ukrainian mountain defenses, to assure safe transportation of the goods via Poland to Western Ukraine. There, they are distributed by the Ukrainian Vitreoretinal Society to where they are needed considerable. The initiative is believed to be the most active and organized humanitarian help initiatives sustaining eye trauma in the Russian invasion of Ukraine.

By Product Type

Handheld
Tabletop
Doppler
Catheter Based
Others

By Volume Scan

Annular
Raster
Radial
Others

By Technology

Frequency Domain
Spatially Encoded Frequency Domain
Time Domain
Others

By Application

Ophthalmology
Cardiology
Dermatology
Oncology
Others

By End-User

Hospitals
Specialty Clinics
Others

By Region

North America
- U.S.
- Canada
- Mexico

Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe

South America
- Brazil
- Argentina
- Rest of South America

Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific

Middle East and Africa

Key Developments

In January 2023, Thorlabs acquired JML Optical, a US-based precision optics firm. The acquisition of JML Optical broadens Thorlabs' optical elements offerings. Cashing on JML's optic abilities and manufacturing & innovation presence in Rochester, New York allows Thorlabs to provide revolutionary innovations for the photonics market.
In February 2023, NIDEK launched AL-Scan M Optical Biometer and MV-1 Myopia Viewer software. The AL-Scan is crucial for assessing young children and provides smooth patient flow. The biometer measures axial length, which is believed to be an perfect parameter for evaluating myopia.
In October 2022, the European Association of Neurosurgical Societies and ZEISS Medical Technology formed a strategic cooperation (EANS). The business expects that through this association, it expects to be capable of assisting in the training and additional education of neurosurgical professionals, facilitating the exchange of knowledge between users and medical equipment manufacturers, and enhancing scientific progress in the domain of neurosurgery.

Competitive Landscape

The major global players in the market include: Thorlabs, Inc., ZEISS, Topcon Corporation, Leica Microsystems, NIDEK CO., LTD., Heidelberg Engineering Inc., Alcon Inc., Canon Medical Systems, USA., Visionix Ltd. , Abbott, Icare USA, Inc., and OPTOPOL Technology Sp among others.

Why Purchase the Report?

To visualize the global optical coherence tomography market segmentation based on product type, volume scan, technology, application, end-user and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of optical coherence tomography market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key product of all the major players.

The global optical coherence tomography market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Volume Scan
3.3. Snippet by Technology
3.4. Snippet by Application
3.5. Snippet by End-User
3.6. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Cases of Ophthalmic Disorder
  - 4.1.1.2. Increasing Number of Market Developments
- 4.1.2. Restraints
  - 4.1.2.1. High Optical Coherence Tomography Device Cost
  - 4.1.2.2. Ophthalmologists Workforce Shortage
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. End-User Trend
5.7. SWOT Analysis
5.8. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Handheld*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Tabletop
- 7.2.4. Doppler
- 7.2.5. Catheter Based
- 7.2.6. Others

8. By Volume Scan

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Volume Scan
- 8.1.2. Market Attractiveness Index, By Volume Scan
8.2. Annular*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.2.3. Raster
- 8.2.4. Radial
- 8.2.5. Others

9. By Technology

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.1.2. Market Attractiveness Index, By Technology
9.2. Frequency Domain*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Spatially Encoded Frequency Domain
9.4. Time Domain
9.5. Others

10. By Application

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.1.2. Market Attractiveness Index, By Application
10.2. Ophthalmology*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Cardiology
10.4. Dermatology
10.5. Oncology
10.6. Others

11. By End-User

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.1.2. Market Attractiveness Index, By End-User
11.2. Hospitals*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Specialty Clinics
11.4. Others

12. By Region

12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.2. Market Attractiveness Index, By Region
12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Volume Scan
- 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.2.8.1. U.S.
  - 12.2.8.2. Canada
  - 12.2.8.3. Mexico
12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Volume Scan
- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.3.8.1. Germany
  - 12.3.8.2. UK
  - 12.3.8.3. France
  - 12.3.8.4. Italy
  - 12.3.8.5. Spain
  - 12.3.8.6. Rest of Europe
12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Volume Scan
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.4.8.1. Brazil
  - 12.4.8.2. Argentina
  - 12.4.8.3. Rest of South America
12.5. Asia-Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Volume Scan
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.5.8.1. China
  - 12.5.8.2. India
  - 12.5.8.3. Japan
  - 12.5.8.4. Australia
  - 12.5.8.5. Rest of Asia-Pacific
12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Volume Scan
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

13. Competitive Landscape

13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis

14. Company Profiles

14.1. Thorlabs, Inc.*
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
14.2. ZEISS
14.3. Topcon Corporation
14.4. Leica Microsystems
14.5. NIDEK CO., LTD.
14.6. Heidelberg Engineering Inc.
14.7. Alcon Inc.
14.8. Canon Medical Systems, USA.
14.9. Visionix Ltd.
14.10. Abbott
14.11. Icare USA, Inc.
14.12. OPTOPOL Technology Sp